Ascelia Pharma – Presentation of Full year and Q4 report

You can already now sign up for the event and send in your questions. You don’t have to participate live to submit questions for the event.

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on February 7th. at 1:30 PM.

In 2024, the company received positive headline data from the Orviglance SPARKLE Phase 3 study, along with the full data package from this study, which meets both the primary and secondary endpoints. At the same time, the company completed a capital increase to strengthen its financial position ahead of finalizing a partnership agreement. Key focus areas for 2025 include securing a partnership agreement and submitting an NDA application to FDA for the approval of Orviglance.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmo, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 10.30 23-01-2025